Xencor’s (XNCR) “Neutral” Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their neutral rating on shares of Xencor (NASDAQ:XNCR) in a report issued on Tuesday morning, Marketbeat Ratings reports. They currently have a $13.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $18.00.

Other analysts have also recently issued reports about the company. Truist Financial assumed coverage on Xencor in a report on Monday, November 24th. They set a “buy” rating and a $29.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Barclays upped their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.38.

Xencor Trading Down 1.3%

Shares of Xencor stock opened at $11.89 on Tuesday. Xencor has a twelve month low of $6.92 and a twelve month high of $18.69. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12. The business has a 50-day moving average price of $12.15 and a 200-day moving average price of $13.32. The firm has a market cap of $872.01 million, a price-to-earnings ratio of -9.59 and a beta of 0.95.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The company had revenue of $28.24 million for the quarter, compared to the consensus estimate of $29.97 million. During the same period in the previous year, the business earned ($0.62) earnings per share. The firm’s revenue for the quarter was down 46.6% on a year-over-year basis. Equities research analysts anticipate that Xencor will post -3.68 EPS for the current fiscal year.

Insider Transactions at Xencor

In related news, SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total value of $36,495.00. Following the transaction, the senior vice president owned 78,685 shares of the company’s stock, valued at $885,206.25. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 2,502 shares of Xencor stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $11.02, for a total transaction of $27,572.04. Following the sale, the vice president owned 263,831 shares of the company’s stock, valued at $2,907,417.62. The trade was a 0.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 44,020 shares of company stock worth $499,817. 5.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Xencor

A number of hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL increased its position in shares of Xencor by 160.3% during the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after acquiring an additional 4,393,579 shares during the period. Legal & General Group Plc boosted its holdings in shares of Xencor by 603.7% in the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after purchasing an additional 1,092,095 shares during the period. State Street Corp grew its stake in Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after purchasing an additional 833,423 shares in the last quarter. Jefferies Financial Group Inc. grew its stake in Xencor by 620.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after purchasing an additional 620,440 shares in the last quarter. Finally, RTW Investments LP increased its holdings in Xencor by 8.9% during the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after purchasing an additional 556,407 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.